Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.
Noninvasive imaging may be the best way to screen for NAFLD in this population.
The American Academy of Pediatrics recommends HIV testing for youth ages 15 and older. Updated guidance now includes PrEP and PEP.
Disparities in who gets a PrEP prescription and who doesn’t show up even among those with access to care.
The federal HIV funding goes to 31 local housing programs and seven global data collection centers.
Little HIV prevention research has included pregnant women for fear of adverse birth outcomes.
Immigrants and girls had worse HIV outcomes in this study.
The small single-site study will need to be replicated in a larger group of adolescents.
Better integration and transition planning was associated with higher rates of viral suppression among youth with HIV.
Supporting universal access to care and quality-of-life check-ins may be associated with better quality of life for teens with HIV.
The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.
Study also finds that trans girls are more likely to receive gender-affirming care than trans boys.
Iris House encourages young people to get tested.
However, even as new cases climbed, deaths declined.
Compared with efavirenz-based regimens, dolutegravir-containing ones resulted in fewer switches and better viral control.
The number of days to an undetectable viral load dropped by nearly two weeks, but there’s more work to do.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.